vs
ホロジック(HOLX)とRUSH ENTERPRISES INC \TX\(RUSHA)の財務データ比較。上の社名をクリックして会社を切り替えられます
RUSH ENTERPRISES INC \TX\の直近四半期売上が大きい($1.7B vs $1.0B、ホロジックの約1.6倍)。ホロジックの純利益率が高く(17.1% vs 3.7%、差は13.4%)。ホロジックの前年同期比売上増加率が高い(2.5% vs -9.0%)。RUSH ENTERPRISES INC \TX\の直近四半期フリーキャッシュフローが多い($411.6M vs $215.2M)。過去8四半期でホロジックの売上複合成長率が高い(1.5% vs -6.8%)
Hologic Inc.は米国発の医療テクノロジー企業で、女性の健康分野を事業の中核に据えている。診断機器、外科手術用機器、医療画像機器などの各種医療機器を開発・販売し、世界中の医療現場に高品質な製品とソリューションを提供している。
ラッシュ・エンタープライズは米国テキサス州ニューブラウンフェルズに本拠を置く商用車ディーラーで、傘下のRush Truck Centersを通じて新車・中古トラックを主力販売している。2019年時点で米国20州に200店舗以上、カナダに14拠点を展開し、2020年にフォーチュン500入りを果たした。
HOLX vs RUSHA — 直接比較
損益計算書 — Q1 FY2026 vs Q1 FY2026
| 指標 | ||
|---|---|---|
| 売上 | $1.0B | $1.7B |
| 純利益 | $179.1M | $61.7M |
| 粗利率 | 56.0% | 20.4% |
| 営業利益率 | 22.6% | 4.9% |
| 純利益率 | 17.1% | 3.7% |
| 売上前年比 | 2.5% | -9.0% |
| 純利益前年比 | -10.9% | 1.8% |
| EPS(希薄化後) | $0.79 | $0.77 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | — | $1.7B | ||
| Q4 25 | $1.0B | $1.7B | ||
| Q3 25 | $1.0B | $1.8B | ||
| Q2 25 | $1.0B | $1.8B | ||
| Q1 25 | $1.0B | $1.8B | ||
| Q4 24 | $1.0B | $1.9B | ||
| Q3 24 | $988.0M | $1.8B | ||
| Q2 24 | $1.0B | $1.9B |
| Q1 26 | — | $61.7M | ||
| Q4 25 | $179.1M | $64.3M | ||
| Q3 25 | $187.2M | $66.7M | ||
| Q2 25 | $194.9M | $72.4M | ||
| Q1 25 | $-17.4M | $60.3M | ||
| Q4 24 | $201.0M | $74.8M | ||
| Q3 24 | $178.6M | $79.1M | ||
| Q2 24 | $194.5M | $78.7M |
| Q1 26 | — | 20.4% | ||
| Q4 25 | 56.0% | 20.8% | ||
| Q3 25 | 55.6% | 21.0% | ||
| Q2 25 | 56.3% | 20.7% | ||
| Q1 25 | 37.5% | 20.3% | ||
| Q4 24 | 56.8% | 19.3% | ||
| Q3 24 | 56.4% | 21.0% | ||
| Q2 24 | 55.4% | 20.2% |
| Q1 26 | — | 4.9% | ||
| Q4 25 | 22.6% | 5.5% | ||
| Q3 25 | 22.6% | 5.6% | ||
| Q2 25 | 24.9% | 6.0% | ||
| Q1 25 | -0.7% | 5.2% | ||
| Q4 24 | 22.5% | 5.8% | ||
| Q3 24 | 23.3% | 6.7% | ||
| Q2 24 | 24.1% | 6.4% |
| Q1 26 | — | 3.7% | ||
| Q4 25 | 17.1% | 3.8% | ||
| Q3 25 | 17.8% | 3.7% | ||
| Q2 25 | 19.0% | 3.9% | ||
| Q1 25 | -1.7% | 3.4% | ||
| Q4 24 | 19.7% | 3.9% | ||
| Q3 24 | 18.1% | 4.4% | ||
| Q2 24 | 19.2% | 4.1% |
| Q1 26 | — | $0.77 | ||
| Q4 25 | $0.79 | $0.81 | ||
| Q3 25 | $0.84 | $0.83 | ||
| Q2 25 | $0.86 | $0.90 | ||
| Q1 25 | $-0.08 | $0.73 | ||
| Q4 24 | $0.87 | $-95.13 | ||
| Q3 24 | $0.75 | $0.97 | ||
| Q2 24 | $0.82 | $97.00 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | ||
|---|---|---|
| 現金・短期投資手元流動性 | $2.4B | — |
| 総負債低いほど良い | $2.5B | $277.8M |
| 株主資本純資産 | $5.2B | $2.3B |
| 総資産 | $9.2B | $4.5B |
| 負債/資本比率低いほどレバレッジが低い | 0.48× | 0.12× |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | — | ||
| Q4 25 | $2.4B | $212.6M | ||
| Q3 25 | $2.2B | $242.0M | ||
| Q2 25 | $1.9B | $211.1M | ||
| Q1 25 | $1.6B | $228.7M | ||
| Q4 24 | $2.0B | $228.1M | ||
| Q3 24 | $2.3B | $185.1M | ||
| Q2 24 | $2.4B | $167.3M |
| Q1 26 | — | $277.8M | ||
| Q4 25 | $2.5B | $274.8M | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | $408.4M | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — |
| Q1 26 | — | $2.3B | ||
| Q4 25 | $5.2B | $2.2B | ||
| Q3 25 | $5.0B | $2.2B | ||
| Q2 25 | $4.8B | $2.2B | ||
| Q1 25 | $4.6B | $2.2B | ||
| Q4 24 | $4.8B | $2.1B | ||
| Q3 24 | $5.1B | $2.1B | ||
| Q2 24 | $5.0B | $2.0B |
| Q1 26 | — | $4.5B | ||
| Q4 25 | $9.2B | $4.4B | ||
| Q3 25 | $9.0B | $4.6B | ||
| Q2 25 | $8.8B | $4.7B | ||
| Q1 25 | $8.5B | $4.7B | ||
| Q4 24 | $8.7B | $4.6B | ||
| Q3 24 | $9.2B | $4.6B | ||
| Q2 24 | $8.9B | $4.5B |
| Q1 26 | — | 0.12× | ||
| Q4 25 | 0.48× | 0.12× | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | 0.19× | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | ||
|---|---|---|
| 営業キャッシュフロー直近四半期 | $229.9M | — |
| フリーキャッシュフロー営業CF - 設備投資 | $215.2M | $411.6M |
| FCFマージンFCF / 売上 | 20.5% | 24.4% |
| 設備投資強度設備投資 / 売上 | 1.4% | 2.0% |
| キャッシュ転換率営業CF / 純利益 | 1.28× | — |
| 直近12ヶ月FCF直近4四半期 | $1.0B | $828.4M |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | — | ||
| Q4 25 | $229.9M | $112.9M | ||
| Q3 25 | $355.1M | $367.8M | ||
| Q2 25 | $343.3M | $227.6M | ||
| Q1 25 | $169.4M | $153.5M | ||
| Q4 24 | $189.3M | $392.3M | ||
| Q3 24 | $367.0M | $111.7M | ||
| Q2 24 | $405.8M | $270.6M |
| Q1 26 | — | $411.6M | ||
| Q4 25 | $215.2M | $31.9M | ||
| Q3 25 | $341.4M | $271.2M | ||
| Q2 25 | $330.5M | $113.8M | ||
| Q1 25 | $153.9M | $45.1M | ||
| Q4 24 | $172.5M | $263.5M | ||
| Q3 24 | $350.6M | $-20.0M | ||
| Q2 24 | $385.3M | $177.2M |
| Q1 26 | — | 24.4% | ||
| Q4 25 | 20.5% | 1.9% | ||
| Q3 25 | 32.5% | 15.2% | ||
| Q2 25 | 32.3% | 6.2% | ||
| Q1 25 | 15.3% | 2.6% | ||
| Q4 24 | 16.9% | 13.7% | ||
| Q3 24 | 35.5% | -1.1% | ||
| Q2 24 | 38.1% | 9.1% |
| Q1 26 | — | 2.0% | ||
| Q4 25 | 1.4% | 4.8% | ||
| Q3 25 | 1.3% | 5.4% | ||
| Q2 25 | 1.3% | 6.2% | ||
| Q1 25 | 1.5% | 6.2% | ||
| Q4 24 | 1.6% | 6.7% | ||
| Q3 24 | 1.7% | 7.3% | ||
| Q2 24 | 2.0% | 4.8% |
| Q1 26 | — | — | ||
| Q4 25 | 1.28× | 1.75× | ||
| Q3 25 | 1.90× | 5.51× | ||
| Q2 25 | 1.76× | 3.14× | ||
| Q1 25 | — | 2.55× | ||
| Q4 24 | 0.94× | 5.25× | ||
| Q3 24 | 2.05× | 1.41× | ||
| Q2 24 | 2.09× | 3.44× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
RUSHA
| New and used commercial vehicle sales | $955.1M | 57% |
| Aftermarket products and services sales | $627.2M | 37% |
| Lease and rental sales | $92.3M | 5% |
| Finance and insurance | $5.6M | 0% |